You are here

13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
King George Hospital
Visakhapatnam, Andhra Pradesh, 530002 India
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Indian adults subjects between 50 and 65 years of age and indian children between 6 and
17years of age, determined by clinical judgment to be eligible for 13vPnC vaccination.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Any contraindication to 13vPnC vaccination, vaccination with any pneumococcal vaccine
within the last year

NCT02034877
Pfizer
Completed
13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now